Ixabepilone development across the breast cancer continuum: a paradigm shift
Nuhad K IbrahimDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAAbstract: The epothilone analog ixabepilone exhibits reduced susceptibility to several important tumor survival mechanisms that limit the efficacy of taxanes and anthracyclines. A...
Main Author: | Nuhad K Ibrahim |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2010-06-01
|
Series: | Cancer Management and Research |
Online Access: | http://www.dovepress.com/ixabepilone-development-across-the-breast-cancer-continuum-a-paradigm--a4719 |
Similar Items
-
Ixabepilone: Overview of Effectiveness, Safety, and Tolerability in Metastatic Breast Cancer
by: Nuhad K. Ibrahim
Published: (2021-07-01) -
Ixabepilone: new perspectives for its use in breast cancer
by: A. A. Mescheryakov, et al.
Published: (2018-11-01) -
Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer
by: Katherine H. Rak Tkaczuk
Published: (2011-01-01) -
Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer
by: Katherine H. Rak Tkaczuk
Published: (2011-01-01) -
Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
by: Massimo Cristofanilli
Published: (2012-01-01)